Vedanta Biosciences to Present at the 9th International Human Microbiome Consortium Congress

Rhea-AI Summary

Vedanta Biosciences, a clinical-stage biopharmaceutical company, announced that Bernat Olle, CEO, will present at the 9th International Human Microbiome Consortium Congress in Kobe, Japan from November 8-10, 2022. The presentation, titled Development of a Defined Bacterial Consortium for the Prevention of Recurrent Clostridioides Difficile Infection, will showcase Phase 2 results of VE303, a therapeutic candidate for preventing recurrent Clostridioides difficile infection, which showed a 31.7% absolute risk reduction in recurrence compared to placebo.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced that Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences, will present at the 9^th International Human Microbiome Consortium Congress (IHMC), being held from November 8 – 10, 2022 in Kobe, Japan.

The presentation is titled, Development of a Defined Bacterial Consortium for the Prevention of Recurrent Clostridioides Difficile Infection, and will be held at 14:50 p.m. JST on November 10th. The presentation will include results of the Phase 2 CONSORTIUM study of VE303 in Clostridioides difficile infection (CDI).

About VE303
VE303 is a defined bacterial consortium therapeutic candidate designed for the prevention of recurrent Clostridioides difficile infection (rCDI). It consists of eight strains that were rationally selected using Vedanta’s discovery engine. VE303 is produced from pure, clonal bacterial cell banks, which yield a standardized drug product in powdered form and bypasses the need to rely on direct sourcing from donor fecal material of inconsistent composition. Vedanta reported positive topline results in October 2021 from the Phase 2 CONSORTIUM trial, in which VE303 was associated with a 31.7% absolute risk reduction in the rate of recurrence when compared with placebo, representing a greater than 80% reduction in the odds of a CDI recurrence. Vedanta believes VE303 has the potential to become a first-in-class therapeutic based on a rationally defined bacterial consortium. Vedanta Biosciences received a $5.4 million research grant from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) in 2017 and a contract of up to $81.9 million from Biomedical Advanced Research and Development Authority (BARDA) in 2020 to support clinical studies of VE303. VE303 was granted Orphan Drug Designation in 2017 by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent CDI.

About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, food allergy, liver disease, and cancer. These investigational therapies are grounded in pioneering research – published in leading journals including Science, Nature, and Cell – to identify beneficial bacteria that live symbiotically within the healthy human gut, fight pathogens and induce a range of potent immune responses. Vedanta Biosciences controls a foundational portfolio of more than 60 patents and has built what it believes is one of the largest libraries of bacteria derived from the human microbiome. Proprietary capabilities include deep expertise in consortium design, vast datasets from human interventional studies, and CGMP-compliant manufacturing of oral Live Biotherapeutic Product (LBP) candidates containing pure, clonally-derived bacterial consortia in powdered form. Vedanta Biosciences was founded by PureTech Health (Nasdaq: PRTC, LSE: PRTC) and a global team of scientific co-founders who pioneered the modern understanding of the cross-talk between the microbiome and the immune system.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005259/en/

Media

Nichole Sarkis

+1 774 278 8273

nichole@tenbridgecommunications.com

Investors

Chris Brinzey

+ 1 617 835 9304

Chris.Brinzey@westwicke.com

Source: Vedanta Biosciences

FAQ

What is the significance of VE303 in preventing Clostridioides difficile infection?

VE303 is a therapeutic candidate showing a 31.7% reduction in the recurrence of Clostridioides difficile infection compared to placebo.

When and where will Vedanta Biosciences present their research on VE303?

Vedanta Biosciences will present their research on VE303 on November 10, 2022, at the 9th International Human Microbiome Consortium Congress in Kobe, Japan.

What are the key results from the Phase 2 CONSORTIUM study of VE303?

The Phase 2 CONSORTIUM study showed that VE303 was associated with more than an 80% reduction in the odds of recurrent Clostridioides difficile infection.

What grants and contracts has Vedanta Biosciences received for VE303?

Vedanta received a $5.4 million grant from CARB-X in 2017 and a contract of up to $81.9 million from BARDA in 2020 to support VE303 clinical studies.

What designation has VE303 received from the FDA?

VE303 received Orphan Drug Designation from the U.S. FDA for the prevention of recurrent Clostridioides difficile infection.